


FT-1518

Cat. No.:	HY-107363		
CAS No.:	1313026-58-2		
Molecular Formula:	C ₂₀ H ₂₆ N ₈ O		
Molecular Weight:	394.47		
Target:	mTOR		
Pathway:	PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 5 mg/mL (12.68 mM; ultrasonic and warming and heat to 60°C)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM	2.5350 mL	12.6752 mL	25.3505 mL
		5 mM	0.5070 mL	2.5350 mL	5.0701 mL
10 mM		0.2535 mL	1.2675 mL	2.5350 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 0.5 mg/mL (1.27 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.5 mg/mL (1.27 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 0.5 mg/mL (1.27 mM); Clear solution 				

BIOLOGICAL ACTIVITY

Description	FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity.	
IC₅₀ & Target	mTORC1	mTORC2
In Vitro	FT-1518 is a new generation selective, potent and oral bioavailable mTORC1 and mTORC2 inhibitor, and exhibits antitumor activity. FT-1518 displays significant growth inhibitory activity against a large panel of hematologic and solid tumor cell lines	

with most activities falling into low nanomolar range. FT-1518 causes potent inhibition of the mTOR pathway biomarkers (mTORC 1 & 2 biomarkers [pAkt(S473) and pS6(S240/244) or p70 S6K], no inhibition of PI3K biomarker [pAkt(T308)]) in cells^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

FT-1518 exhibits dose-dependent and higher tumor growth inhibition (TGI) in multiple solid tumor xenografts^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Alain C. Mita, et al. Abstract 137: FT-1518, a new generation selective and potent mTORC1 and mTORC2 inhibitor: an in vitro and in vivo profile. Cancer Res 2017;77(13 Suppl).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA